File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: In-vitro study of arsenic trioxide and chemotherapeutic agents in small cell lung carcinoma

TitleIn-vitro study of arsenic trioxide and chemotherapeutic agents in small cell lung carcinoma
Authors
KeywordsArsenic trioxide
Small cell lung cancer
Issue Date2011
PublisherLippincott Williams & Wilkins.
Citation
The 14th World Conference on Lung Cancer (WCLC 2011), Amsterdam, The Netherlands, 3-7 July 2011. In Journal of Thoracic Oncology, 2011, v. 6 suppl. 2, bk 2, p. S933, abstract no. P2.023 How to Cite?
AbstractBACKGROUND: Arsenic trioxide (ATO), an anti-tumor agent with multi-faceted mechanisms of action, has become a breakthrough treatment for acute promyelocytic leukemia in recent years. There have been preliminary data about the potential activity of ATO in solid tumours, including small cell lung cancer (SCLC). As SCLC is considered a chemo-sensitive malignancy, we conducted an in-vitro study examining the cytotoxic effects as well as the mechanisms of ATO, clinically effective chemotherapeutic agents, or a combin...
DescriptionThis journal suppl.divided into 2 bks entitled Proceedings of the 14th World Conference on Lung Cancer 2011
Poster Session 2 – Preclinical Models
Persistent Identifierhttp://hdl.handle.net/10722/137779
ISSN
2015 Impact Factor: 5.04
2015 SCImago Journal Rankings: 2.597

 

DC FieldValueLanguage
dc.contributor.authorZheng, Cen_US
dc.contributor.authorLam, SKen_US
dc.contributor.authorHo, JCMen_US
dc.date.accessioned2011-08-26T14:33:15Z-
dc.date.available2011-08-26T14:33:15Z-
dc.date.issued2011en_US
dc.identifier.citationThe 14th World Conference on Lung Cancer (WCLC 2011), Amsterdam, The Netherlands, 3-7 July 2011. In Journal of Thoracic Oncology, 2011, v. 6 suppl. 2, bk 2, p. S933, abstract no. P2.023en_US
dc.identifier.issn1556-0864-
dc.identifier.urihttp://hdl.handle.net/10722/137779-
dc.descriptionThis journal suppl.divided into 2 bks entitled Proceedings of the 14th World Conference on Lung Cancer 2011-
dc.descriptionPoster Session 2 – Preclinical Models-
dc.description.abstractBACKGROUND: Arsenic trioxide (ATO), an anti-tumor agent with multi-faceted mechanisms of action, has become a breakthrough treatment for acute promyelocytic leukemia in recent years. There have been preliminary data about the potential activity of ATO in solid tumours, including small cell lung cancer (SCLC). As SCLC is considered a chemo-sensitive malignancy, we conducted an in-vitro study examining the cytotoxic effects as well as the mechanisms of ATO, clinically effective chemotherapeutic agents, or a combin...-
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins.-
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.subjectArsenic trioxide-
dc.subjectSmall cell lung cancer-
dc.titleIn-vitro study of arsenic trioxide and chemotherapeutic agents in small cell lung carcinomaen_US
dc.typeConference_Paperen_US
dc.identifier.emailZheng, C: alds324@hku.hken_US
dc.identifier.emailLam, SK: sklam77@hku.hken_US
dc.identifier.emailHo, JCM: jhocm@hku.hk-
dc.identifier.authorityHo, JCM=rp00258en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1097/01.JTO.0000399290.73317.eb-
dc.identifier.hkuros190422en_US
dc.identifier.volume6-
dc.identifier.issuesuppl. 2, bk 2-
dc.identifier.spageS933-
dc.identifier.epageS933-
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 130802-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats